Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma

Abstract EN

Background.

The most appropriate therapy for papillary microcarcinoma (PMC) is controversial.

Methods.

We reviewed the therapy and outcome of 407 patients with PMC.

Results.

Three hundred-eighty patients underwent total thyroidectomy, and 349 patients received I-131 therapy.

The median followup was 5.3 years.

Forty patients developed recurrent disease.

On univariate analysis, development of disease recurrence was correlated with histological tumor size > 0.8 cm (P=0.0104), age < 45 years (P=0.043), and no I-131 therapy (P<0.0001).

On multivariate analysis, histological tumor size > 0.8 cm, positive lymph nodes, and no I-131 therapy were significant.

The 5-year RFS for patients treated with I-131 was 95.0% versus 78.6% (P<0.0001) for patients not treated with I-131.

Patients with lymph node metastasis who did not receive I-131 had a 5-year RFS of 42.9% versus 93.2% (P<0.0001) for patients who received I-131.

Conclusions.

Recommend I-131 remnant ablation for patients with PMC, particularly patients with lymph node metastasis.